SOTIO Presents Data on SOT201 Immunocytokine and Other Programs at SITC Annual Meeting

October 31, 2023 Source: Press Release, Prague, Basel, Boston SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will be presenting new preclinical data at the Society for Immunotherapy of Cancer’s 38th Annual Meeting taking place November 1-5, 2023 in San Diego, California. Data to be presented include new preclinical results supporting the continued development of SOT201, a next-generation PD-1-inhibiting cytokine that SOTIO is progressing toward a planned first-in-human study in the second quarter of 2024. SOT201 is an antibody-cytokine fusion protein that could improve upon the efficacy of approved checkpoint inhibitors by combining PD-1 blockade with IL-15 immune stimulation in a single therapeutic construct. Additional poster presentations at the meeting will include preclinical data on the synergistic effects of SOTIO’s IL-15 superagonist in combination with CAR T-cell therapies, as well as data on SOTIO’s IL-15 superagonist nanrilkefusp alfa. Presentation details are as follows: Title: “SOT201 is a novel cis-acting immunocytokine targeting IL-15Rβγ and PD-1 to reinvigorate PD-1+ tumor infiltrating lymphocytes and potentiate anti-tumor efficacy” Number: 1087 Date: November 3, 2023 Presenter: Irena Adkins, Martin Steegmaier Title: “Combination with IL-15Rβγ superagonist, Nanrilkefusp alfa, enhances CAR T and BOXR T cell anti-tumor activity” Number: 815 Date: November 3, 2023 Presenter: Amy Jensen-Smith Title: “Nanrilkefusp alfa, a high-affinity IL-15Rβγ agonist, promotes an innate and adaptive anti-tumor inflammatory environment as single agent or combined with anti-PD-1 in patients with advanced cancers” Number: 713 Date: November 3, 2023 Presenter: Petr Danek, Lenka Palova Jelinkova Posters will be available after presentations conclude HERE .

The release as fetched from its publisher. sotio.com ↗